Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

August 10, 2020

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

July 13, 2020

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 8, 2020

Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

July 6, 2020

Revolution Medicines Announces Proposed Public Offering of Common Stock

June 30, 2020

Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

June 22, 2020

Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

June 22, 2020

Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

June 18, 2020

Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

June 9, 2020

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

May 19, 2020

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 40

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations